BR0110210A - Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica - Google Patents

Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica

Info

Publication number
BR0110210A
BR0110210A BR0110210-9A BR0110210A BR0110210A BR 0110210 A BR0110210 A BR 0110210A BR 0110210 A BR0110210 A BR 0110210A BR 0110210 A BR0110210 A BR 0110210A
Authority
BR
Brazil
Prior art keywords
treatment
fibromyalgia
chronic fatigue
fatigue syndrome
compounds
Prior art date
Application number
BR0110210-9A
Other languages
English (en)
Inventor
Robert B Mccall
Robert C Marshall
David W Robertson
Thomas M Ashley
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0110210A publication Critical patent/BR0110210A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSTOS PARA O TRATAMENTO DE FIBROMIALGIA E SìNDROME DE FADIGA CRÈNICA". A presente invenção propõe o emprego de um composto heterocíclico do tipo amina, um composto do tipo fenil-azaciclo-alcano substituído, ou um composto do tipo cabergolina para preparar um medicamento para o tratamento de sintomas de síndrome de fibromialgia ou de síndrome de fadiga crónica.
BR0110210-9A 2000-04-21 2001-04-17 Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica BR0110210A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19895900P 2000-04-21 2000-04-21
US20056900P 2000-04-28 2000-04-28
PCT/US2001/010807 WO2001081343A2 (en) 2000-04-21 2001-04-17 Compounds for treating fibromyalgia and chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
BR0110210A true BR0110210A (pt) 2003-01-28

Family

ID=26894316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110210-9A BR0110210A (pt) 2000-04-21 2001-04-17 Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica

Country Status (16)

Country Link
US (3) US6448258B2 (pt)
EP (1) EP1274430B1 (pt)
JP (1) JP2004502650A (pt)
KR (1) KR20040007215A (pt)
CN (3) CN1450898A (pt)
AR (3) AR028355A1 (pt)
AT (1) ATE312608T1 (pt)
AU (2) AU5311401A (pt)
BR (1) BR0110210A (pt)
CA (1) CA2405565A1 (pt)
DE (1) DE60115872T2 (pt)
DK (1) DK1274430T3 (pt)
ES (1) ES2253370T3 (pt)
NZ (3) NZ531172A (pt)
PE (1) PE20011212A1 (pt)
WO (1) WO2001081343A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
AU5522301A (en) * 2000-04-21 2001-11-26 Upjohn Co Treatment of fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
NZ524741A (en) * 2000-08-16 2005-01-28 Upjohn Co Heterocyclic amines, phenylazacycloalkanes, cabergoline and aromatic bicyclic amines for the treatment of alcohol, nicotine and drug addiction
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
MXPA05003513A (es) * 2002-10-04 2005-06-03 Pharmacia Corp Composiciones farmaceuticas para tratamiento de enfermedad de parkinson.
WO2004032853A2 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
EP1904483A1 (en) 2005-07-13 2008-04-02 F. Hoffmann-Roche AG Benzimidazole derivatives as 5-ht6,5-ht24
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
BR112015022942B1 (pt) * 2013-03-15 2022-02-22 Incyte Holdings Corporation Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
NZ763740A (en) 2014-04-23 2023-06-30 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
DE102014008742A1 (de) * 2014-06-12 2015-12-17 Daimler Ag Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
EP3294337A1 (en) 2015-05-13 2018-03-21 A.Carlsson Research AB Treatment of debilitating fatigue
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
JP3176063B2 (ja) * 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
WO1995004056A1 (en) * 1993-07-27 1995-02-09 The Upjohn Company Heterocyclic amines having central nervous system activity
JPH1053525A (ja) * 1996-06-06 1998-02-24 Bitakain Seiyaku Kk 疼痛治療剤
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Also Published As

Publication number Publication date
US6448258B2 (en) 2002-09-10
DE60115872D1 (de) 2006-01-19
KR20040007215A (ko) 2004-01-24
NZ522112A (en) 2004-10-29
ATE312608T1 (de) 2005-12-15
WO2001081343A3 (en) 2002-02-28
CN1450898A (zh) 2003-10-22
AU5311401A (en) 2001-11-07
CN1554343A (zh) 2004-12-15
AR039633A2 (es) 2005-03-02
JP2004502650A (ja) 2004-01-29
CN1554341A (zh) 2004-12-15
DE60115872T2 (de) 2006-07-13
CA2405565A1 (en) 2001-11-01
NZ531172A (en) 2005-07-29
US20020004510A1 (en) 2002-01-10
US6555548B2 (en) 2003-04-29
WO2001081343A2 (en) 2001-11-01
AR039632A2 (es) 2005-03-02
PE20011212A1 (es) 2001-11-21
US20020143010A1 (en) 2002-10-03
NZ531171A (en) 2005-03-24
ES2253370T3 (es) 2006-06-01
EP1274430B1 (en) 2005-12-14
DK1274430T3 (da) 2006-02-13
EP1274430A2 (en) 2003-01-15
AU2001253114B2 (en) 2005-08-25
AR028355A1 (es) 2003-05-07
US20030191149A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
BR0110210A (pt) Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica
BR0109703A (pt) Derivados de piperazina
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
ATE408601T1 (de) Fredericamycin-derivate
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
BR0314843A (pt) Novo composto
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
BRPI0412159A (pt) emprego
DE60112960D1 (de) Kondensierte pyridoindolderivate
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.